Skip to main content
SBCSBC Medical Group Holdings IncoBuy Now7.1·$5.69
SBC · Why this verdict

Why SBC Medical Group Holdings Inco (SBC) is rated BUY NOW

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictBUY NOW
Overall score7.1/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis

Engine thesis — one sentence

SBC Medical is a high-quality, attractively valued small cap with a breakout setup and 37.2% upside to the analyst target, though it trades near its 52-week high and the latest quarter missed estimates.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

The business is rated high quality with margins of 28%, a Piotroski F-Score of 9/9, a wide economic moat and 129% free cash flow to net income, giving a quality score of 8.9.

→Stable
Quality breakdown
Expectation
Quality score should stay above 8.0 with free cash flow conversion above 100% of net income.

CounterConcentration risks (2 medium items in the annual risk factors) and a customer-dependent consulting model could erode margins faster than the score implies.

A forward P/E of 10.0x flags the stock as attractively valued, and the analyst target of $7.44 implies 37.2% upside from $5.42.

→Stable
Valuation breakdown
Expectation
Price should move toward the $7.44 analyst target over 12 months.

CounterAnalyst coverage is light at 4 analysts, and the analyst-disagree flag (1.6x) suggests the target may be inflated.

A golden cross with price above all moving averages, RSI 60 and bullish MACD gives momentum of 6.5, passing the 5.5 gate.

→Stable
Chart pattern detection
Expectation
Momentum should stay above 5.5 with price holding above the 200-day moving average.

CounterThe stock is only 1.6% below its 52-week high, so a breakout here can fail at resistance.

The latest quarter reported earnings per share of $0.10 against a $0.12 estimate, a 14.9% miss, after one beat and two in-line results.

↑Improving
Earnings
Expectation
Earnings per share should meet or beat estimates at the 2026-11-13 report.

CounterAveraged over the last four quarters the surprise is +5.1%, so the miss may be noise rather than a trend.

The put/call ratio is elevated at 2.00, indicating hedging demand on a stock otherwise showing bullish signals.

↓Deteriorating
Risk breakdown
Expectation
Put/call ratio should fall below 1.0 as the breakout holds.

CounterOpen interest is zero on both sides, so the ratio reflects a thin options market rather than genuine bearish positioning.

Per-dimension breakdown

Value

7.8/10data confidence 100%
ComponentSub-score
P/E8.6
P/S8.0
EV/EBITDA7.8
Fwd P/E9.2
PEG4.4
Analyst target9.0
  • ▸Forward P/E: 10.5x
  • ▸PEG: 2.10
  • ▸Attractively valued

Quality

8.9/10data confidence 100%
ComponentSub-score
ROE6.3
ROA7.5
Gross margin10.0
Op margin10.0
Net margin10.0
Current ratio9.7
FCF quality9.3
Moat8.4
Rule of 408.2
Piotroski F10.0
  • ▸Strong margins: 28%
  • ▸Excellent cash conversion: 129% FCF/NI
  • ▸Wide economic moat
  • ▸Compounder quality: strong returns + growth

Growth

5.8/10data confidence 33%
ComponentSub-score
Rev growth5.8

Momentum

6.7/10data confidence 100%
ComponentSub-score
RSI5.5
MACD3.5
OBV10.0
MA position9.0
Volume5.7
  • ▸Volume accumulation (rising OBV)
  • ▸Above 200-day MA

Sentiment

7.3/10data confidence 100%
ComponentSub-score
Analyst rating7.1
Price target9.6
erm sentiment5.0
  • ▸Light analyst coverage (4.0) — signal dampened
  • ▸Analyst upside: 54%

Insider

7.3/10data confidence 75%
ComponentSub-score
materiality5.0
holder change10.0
notable moves7.0
  • ▸No net insider activity — $0 (0.000% of mkt cap)
  • ▸Institutions accumulating

Peer rank

7.0/10data confidence 80%
ComponentSub-score
value rank5.5
quality rank6.3
growth rank7.8
  • ▸Attractive P/E vs peers
  • ▸Conservative debt levels

Technical

3.6/10data confidence 100%
ComponentSub-score
bollinger0.0
support resistance1.2
52w position9.6

Risk (lower is worse)

5.9/10data confidence 100%
ComponentSub-score
short interest8.0
days to cover7.3
volatility1.0
implied vol0.0
beta9.7
debt equity9.3
  • ▸High IV: 90%
  • ▸Concentration risks: 2 MED (10-K Item 1A)

Catalyst

7.1/10data confidence 100%
ComponentSub-score
erm5.0
earnings history10.0
earnings timing5.0
surprise avg8.4
  • ▸Earnings in 13 days

How the verdict was assembled

Engine trigger

Deep value: 52% margin of safety. Extreme undervaluation.

Engine technical detail
verdict_path: L4:PATH_A_DEEP_VALUE
Passed (7)
  • MOMENTUM:6.7>=5.5
  • ASYMMETRY:2.5>=1.5
  • INSIDER:OK
  • NEWS_EVENTS:NONE_RECENT
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
  • SECTOR_CONCENTRATION_CAP:sector=Industrials:0/10:self_excluded
Failed (0)

none

Warning (2)
  • 8K_FLAG:3.01
  • EARNINGS_PROXIMITY:13d<=14d (soft)
Reward-to-Risk
2.46
Upside
+30.7%
Downside
12.5%
Sizing output
HALF

Setup— — No clear chart pattern; technical signals are mixed

EdgeInst Constrain — Small cap ($0.6B) below institutional reach

SuitabilityAggressive — MCap $0.6B<$5B

Investment implication

The STRONG_BUY_NOW verdict reflects clean gate clearance against Quality at 8.9 and asymmetric R:R of 2.46.

The strongest dimensions are Quality at 8.9, Value at 7.8, and Sentiment at 7.3; the weakest are Technical at 3.6, Growth at 5.8, and Risk (lower is worse) at 5.9. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 2.46 and an engine sizing output of HALF.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1High Quality Compounder

    Trip ifQuality score falls below 7.0 from the current 8.9.

  • P2Deep Value With Upside

    Trip ifUpside to the analyst target falls below 15% from the current 37.2%.

  • P3Breakout Momentum

    Trip ifPrice falls below the $5.04 stop level, or momentum falls below 5.5.

  • P4Recent Earnings Miss

    Trip ifEPS surprise stays below 0% for 2 consecutive quarters.

  • P5Bearish Options Hedging

    Trip ifPut/call ratio exceeds 4.0 from the current 2.00.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home › Stocks › SBC › Why this verdict